Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2DMPO)

Drug Name
Kanamycin Drug Info
Synonyms
Aspidium; KAN; Kanamicina; Kanamycine; Kanamycinum; Kantrex; Klebcil; KANAMYCIN A; Kanamicina [Italian]; Kanamycin A tetracation; Kanamycin Base; Kanamycin monosulfate; Kanamycin sulfate; Kenamycin A; Liposomal Kanamycin; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin monosulfate (JP15); Kanamycinsulfate (JP15); Kanamycin sulfate (TN); Kanamycin sulfate (USP); Kanamycine [INN-French]; Kanamycinum [INN-Latin]; Kantrex (TN); Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside
Indication
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [1]
Bacterial infection 1A00-1C4Z Approved [2]
Cholangitis Approved [1]
Urinary tract infection GC08 Approved [1]
Therapeutic Class
Antibiotics
Cross-matching ID
PubChem CID
6032
ChEBI ID
CHEBI:17630
CAS Number
CAS 59-01-8
TTD Drug ID
DM2DMPO
VARIDT Drug ID
DR01214

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tetracycline DMZA017 Acne vulgaris ED80 Approved [8]
Framycetin DMF8DNE Acute liver failure DB91 Approved [9]
Netilmicin DMRD1QK Bacterial infection 1A00-1C4Z Approved [10]
Amikacin DM5PDRB Bacteremia 1A73 Approved [11]
Clomocycline DM0ZRMQ Bacterial infection 1A00-1C4Z Approved [12]
Spectinomycin DM0MQ35 Acute gonococcal cervicitis Approved [13]
Paromomycin DM1AGXN Amoebiasis 1A36 Approved [14]
Lymecycline DMOMLHJ Bacterial infection 1A00-1C4Z Approved [15]
Rolitetracycline DMBR5Q7 Acne vulgaris ED80 Approved [16]
Meclocycline DMSFQ8I Bacterial infection 1A00-1C4Z Approved [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Aminoglycoside O-phosphotransferase (aphA6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gentamicin DMKINJO Bacteremia 1A73 Approved [5]
Tobramycin DMUI0CH Bacteremia 1A73 Approved [5]
Framycetin DMF8DNE Acute liver failure DB91 Approved [5]
Netilmicin DMRD1QK Bacterial infection 1A00-1C4Z Approved [5]
Amikacin DM5PDRB Bacteremia 1A73 Approved [5]
Streptomycin DME1LQN Bacterial infection 1A00-1C4Z Approved [5]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Aminoglycoside phosphotransferase (aph-Ib)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gentamicin DMKINJO Bacteremia 1A73 Approved [4]
Tobramycin DMUI0CH Bacteremia 1A73 Approved [4]
Sisomicin DM92P0F N. A. N. A. Approved [18]
Dibekacin DMTX0PZ N. A. N. A. Phase 4 [18]
Drug(s) Metabolized By Kanamycin/gentamycin-resistance enzyme (aacA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gentamicin DMKINJO Bacteremia 1A73 Approved [4]
Tobramycin DMUI0CH Bacteremia 1A73 Approved [4]
Drug(s) Metabolized By Endoglucanase Y (EGY)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gentamicin DMKINJO Bacteremia 1A73 Approved [6]
Colistin DMMD9QE Pseudomonas infection 1B92 Approved [6]
Streptomycin DME1LQN Bacterial infection 1A00-1C4Z Approved [6]
Bacitracin DM5OHYE Blepharoconjunctivitis Approved [6]
Gentamicin DMKINJO Bacteremia 1A73 Approved [6]
Amikacin DM5PDRB Bacteremia 1A73 Approved [6]
Colistin DMMD9QE Pseudomonas infection 1B92 Approved [6]
Streptomycin DME1LQN Bacterial infection 1A00-1C4Z Approved [6]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Affected By T-lymphocyte activation antigen CD86 (CD86)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [19]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [20]
Methotrexate DM2TEOL Anterior urethra cancer Approved [21]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [22]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [23]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [7]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [24]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [7]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [25]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [22]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Aminoglycoside phosphotransferase (aph-Ib) DE5WGIM A0A075C7U3_CAMJU Substrate [4]
Aminoglycoside O-phosphotransferase (aphA6) DEWPAJD KKA6_ACIBA Substrate [5]
Kanamycin/gentamycin-resistance enzyme (aacA) DECXWN8 J3S7E2_CAMCO Substrate [4]
Endoglucanase Y (EGY) DE2M583 A0A256VAC0_LACRE Substrate [6]
Endoglucanase Y (EGY) DE2AZTG A0A256VAC0_LACRE Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Gene/Protein Processing [7]

References

1 Kanamycin FDA Label
2 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
3 SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells. 2002 Jul;7(7):629-38.
4 Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
5 Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
6 Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
7 A plasmacytoid dendritic cell (CD123+/CD11c-) based assay system to predict contact allergenicity of chemicals. Toxicology. 2009 Oct 1;264(1-2):1-9. doi: 10.1016/j.tox.2009.07.021. Epub 2009 Aug 7.
8 The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.
9 Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9.
10 Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6.
11 Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9.
12 Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5.
13 Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
14 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
15 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
16 Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16.
17 Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
18 Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7.
19 Responsiveness of human monocyte-derived dendritic cells to thimerosal and mercury derivatives. Toxicol Appl Pharmacol. 2010 Jul;246(1-2):66-73. doi: 10.1016/j.taap.2010.04.007. Epub 2010 Apr 22.
20 Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
21 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
22 Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
23 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
24 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
25 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.